{{Drugbox
| IUPAC_name        = (2,2,2-trifluoroethoxy)ethene
| image             = Fluroxene.svg
| CAS_number        = 406-90-6
| ATC_prefix        = None
| ATC_suffix        = 
| PubChem           = 9844
| DrugBank          = 
| ChemSpiderID      = 9461
| chemical_formula =
| C=4 | H=5 | F=3 | O=1 
| molecular_weight  = 126.077 g/mol
| SMILES = C=COCC(F)(F)F
| StdInChI          = 1S/C4H5F3O/c1-2-8-3-4(5,6)7/h2H,1,3H2
| StdInChIKey       = DLEGDLSLRSOURQ-UHFFFAOYSA-N
| bioavailability   = 
| protein_bound     = 
| metabolism        = 
| elimination_half-life = 
| excretion         = 
| pregnancy_AU      =  <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US      =  <!-- A / B            / C / D / X -->
| pregnancy_category=  
| legal_AU =  <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA =  <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK =  <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US =  <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status      = 
| routes_of_administration = 
}}

'''Fluroxene''' ([[International Nonproprietary Name|INN]], [[United States Adopted Name|USAN]]; brand name '''Fluoromar'''), or '''2,2,2-trifluoroethyl vinyl ether''', is a [[Inhalational anesthetic#Volatile anesthetic|volatile]], [[inhalational anesthetic]], and was the first [[haloalkane|halogenated hydrocarbon]] anesthetic to be introduced.<ref name="StoeltingHillier2012">{{cite book|author1=Robert K. Stoelting|author2=Simon C. Hillier|title=Pharmacology and Physiology in Anesthetic Practice|url=https://books.google.com/books?id=lHhGtkvOoM0C&pg=PT142|date=11 January 2012|publisher=Lippincott Williams & Wilkins|isbn=978-1-4511-6583-8|pages=142–}}</ref><ref name="BarashCullen2011">{{cite book|author1=Paul G Barash|author2=Bruce F Cullen|author3=Robert K Stoelting |author4=Michael Cahalan |author5=M Christine Stock|title=Clinical Anesthesia|url=https://books.google.com/books?id=vGtSChnRRJ8C&pg=PT113|date=1 January 2011|publisher=Lippincott Williams & Wilkins|isbn=978-1-4511-2297-8|pages=113–}}</ref> It was synthesized in 1951, and was introduced for clinical use in 1954, but was voluntarily withdrawn from the market in 1974 due to its potential flammability and accumulating evidence that it could cause [[organ (biology)|organ]] [[toxicity]].<ref name="BarashCullen2011" /><ref name="StoeltingHillier2012" /><ref name="LichtigerMoya1978">{{cite book|author1=Monte Lichtiger|author2=Frank Moya|title=Introduction to the practice of anesthesia|url=https://books.google.com/books?id=ecZpAAAAMAAJ|date=1 January 1978|publisher=Medical Dept., Harper & Row|isbn=978-0-06-141534-0}}</ref> In any case, prior to being discontinued, it had largely been superseded by [[halothane]].<ref>{{cite book|title=Acta anaesthesiologica Belgica|url=https://books.google.com/books?id=KmsxAAAAIAAJ|year=1974|publisher=Acta Medica Belgica.}}</ref>

==See also==
* [[Vinyl ether]]

==References==
{{Reflist|2}}


{{General anesthetics}}
{{GABAAR PAMs}}

[[Category:General anesthetics]]
[[Category:Ethers]]
[[Category:Organofluorides]]
[[Category:GABAA receptor positive allosteric modulators]]
[[Category:Trifluoromethyl compounds]]
[[Category:Vinyl compounds]]


{{nervous-system-drug-stub}}